Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1373204 | Bioorganic & Medicinal Chemistry Letters | 2007 | 6 Pages |
Primaquine is the drug of choice for the radical cure of Plasmodium vivax malaria, but possesses serious side effects. In this study novel primaquine analogues were designed and synthesized. Lower toxicity was achieved by reducing or eliminating the tendency of forming chemically reactive and toxic intermediates and metabolites. In vitro and in vivo studies found that synthesized compounds were less toxic than the parent compound primaquine, while preserving the desired antimalarial activity. Some of these compounds possess a therapeutic index over 10 times superior to that of the commonly used antimalarial drug chloroquine. These compounds, as well as the underlying design rationale, may find usefulness in the discovery and development of new antimalarial drugs.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide